NCX 470 Phase 3 Glaucoma Trial Results in American Journal of Ophthalmology

The results of a significant clinical trial, Mont Blanc Phase 3, have been made public in a reputable journal, showcasing the efficacy of a new glaucoma treatment. The study, led by Dr. Robert Fechtner, compared the performance of NCX 470 against latanoprost in reducing intraocular pressure (IOP) in patients suffering from open-angle glaucoma or ocular hypertension. The findings indicate that NCX 470, developed by Nicox SA, not only matched but surpassed latanoprost in lowering IOP across all measured time points.

The publication, which appeared online on March 16, 2024, in the American Journal of Ophthalmology, highlights the innovative dual-action mechanism of NCX 470. This mechanism simultaneously enhances both uveoscleral and trabecular outflow, which could position NCX 470 as a vital first-line therapy for IOP reduction in glaucoma.

Nicox SA, an international ophthalmology firm based in Sophia Antipolis, France, is advancing its lead clinical asset, NCX 470, a novel nitric oxide-donating bimatoprost eye drop. The ongoing Denali Phase 3 clinical trial, which is assessing NCX 470's potential in the same patient population, is expected to release its topline results in the second half of 2025. Recruitment for the trial is nearing completion, with 80% of the target patient number already enrolled.

Nicox generates revenue from its product VYZULTA®, which is licensed exclusively to Bausch + Lomb for glaucoma treatment, and ZERVIATE®, which is licensed in various regions for the treatment of allergic conjunctivitis. The company is listed on Euronext Growth Paris and is part of the CAC Healthcare index.

The company's Chief Scientific Officer, Doug Hubatsch, expressed his satisfaction with the publication and anticipation for the Denali trial's results, which will further validate NCX 470's clinical profile. The Mont Blanc study's success is also attributed to the diligent work of the participating study sites.

Nicox continues to focus on developing innovative solutions to preserve vision and enhance ocular health, with NCX 470 at the forefront of its clinical development programs. The company's commitment to advancing eye care is evident through its ongoing trials and partnerships, aiming to provide effective treatments for various ocular conditions.